New humira copycat tested in healthy chinese volunteers
NCT ID NCT07147257
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compared a new biosimilar drug called CHS-1420 to the original Humira (adalimumab) in 238 healthy Chinese adults. Each person received a single injection of either CHS-1420 or Humira, and researchers measured how the drug moved through their blood over time. The goal was to see if the two drugs behave similarly in the body, which is a key step toward offering a more affordable treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CHS-1420 (a proposed biosimilar of adalimumab)
- What this could lead to
- If successful, this could support approval of a more affordable version of Humira for inflammatory conditions.
- What could go wrong
- This is an early-phase trial in healthy people, not patients. It only checks drug levels in the blood, not actual treatment effects or safety in disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ethics Committee of Hopeshine-Minsheng Hospital of Xinzheng
Zhengzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates